The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Evaluation of a novel bispecific targeted toxin in a mouse model of a human metastatic breast cancer
Author(s): 
Pages: 671-673
Year: Issue:  4
Journal: Chinese Journal of Experimental Surgery

Keyword:  ImmunotherapyBreast carcinomaMetastatic brain tumorsModelanimal;
Abstract: Objective To investigate the anticancer effect of the immunotoxin DTATEGF in vitro and in vivo when delivered in mouse model of a human metastatic breast cancer brain tumors.Methods The effects of the immunotoxin were tested for their ability to inhibit the proliferation of 231Br cell line in vitro by methyl thiazol tetrazolium (MTT) assay.In vivo,2 μg of DTATEGF or control Bickel3 was givenby intraperitoneal injection to nude mice with established 231 Br xenografts on their flanks,tumor volumes were measured.On a xenograft intracranial model,1 μg of DTATEGF or control Bickel3 was delivered intracranially,the bioluminescent imaging was performed and Kaplan-Meier survival curves were generated.Results In vitro,DTATEGF could kill 231Br-luc cells and showed an 50% inhibitory dose (IC50) less than 0.01 nmol/L.In vivo,DTATEGF significantly inhibited the growth of 231Br flank tumors (P <0.05),mice with intracranial tumors were treated was successful in providing a survival benefit significantly prolonged relative to controls (87 vs.58 days,P <0.01).Conclusion DTATEGF kills the 231Br-luc cell line in vitro,and it is highly efficacious against human metastatic breast cancer brain tumors.
Related Articles
No related articles found